Key facts
- This page summarizes Keith Crandell's Form 4 filing for DA32 Life Science Tech Acquisition Corp..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Aug 2023, 20:28.
Keith Crandell - 28 Jul 2023 Form 4 Insider Report for DA32 Life Science Tech Acquisition Corp.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 28 Jul 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Aug 2023, 20:28:16 UTC
- Prior SEC filing
- 16 Jun 2023
- Next SEC filing
- 09 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark McDonnell, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Keith Crandell filed Form 4 for DA32 Life Science Tech Acquisition Corp. on 10 Aug 2023.
Change
- Previous filing in this sequence was filed on 16 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DALS
transaction
Class A Common Stock
Other
- Transaction value
- Shares
- -1,600,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 28 Jul 2023
- Ownership
- Through ARCH Venture Fund XI, L.P.
- Footnotes
- F1, F2, F3
DALS
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 650,000
- Date
- 28 Jul 2023
- Ownership
- Through DA32 Sponsor LLC
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On July 28, 2023, the Issuer redeemed all of its outstanding shares of Class A common stock that were publicly traded for a redemption price of approximately $10.31 per share.
Footnote F2
DA32 Sponsor LLC ("Sponsor") owns 650,000 shares of Class A common stock purchased in a private placement.
Footnote F3
As the sole general partner of ARCH Venture Fund XI, L.P. ("AVF"), ARCH Venture Partners XI, L.P. ("AVP LP") may be deemed to beneficially own the securities owned directly by AVF. As the sole general partner of AVP LP, ARCH Venture Partners XI, LLC ("AVP LLC") may be deemed to beneficially own securities owned directly by AVF. As a member of the investment committee of AVP LLC, Keith Crandell may be deemed to beneficially own securities owned directly by AVF. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein.
Footnote F4
As a managing member of Sponsor, AVF may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVF, AVP LP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVP LP, AVP LLC may be deemed to beneficially own securities owned directly by Sponsor. As the members of the investment committee of AVP LLC, each of Kristina Burow, Robert Nelsen, Keith Crandell and Steven Gillis may be deemed to beneficially own securities owned directly by Sponsor. Each of the foregoing entities and individuals is a member of a Section 13(d) group. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein.